Figure 1From: The antitumor immune response in HER-2 positive, metastatic breast cancer patientsThe mean values of the survival (S%) of adenocarcinoma MDA-MB-361 cells, grown for 48 h in nutrient medium with 10% serum from control healthy people, or from breast carcinoma patients with, or without Herceptin (21 μg/ml).Back to article page